Skip to main content

Advertisement

Log in

Alterations in serum activity of hepatocellular enzymes, levels of liver function markers, and liver histology of dogs given high (nephrotoxic) doses of gentamicin

  • Original Article
  • Published:
Comparative Clinical Pathology Aims and scope Submit manuscript

Abstract

This study evaluated the effects of nephrotoxic doses of gentamicin on serum activity of hepatocellular enzymes, levels of liver function markers, and liver histology of dogs. Nine dogs, randomly assigned to two groups (A and B) of five and four dogs each, were used for the study. Baseline values for kidney function, hepatocellular, hepatobiliary, and liver function parameters were assayed initially. Gentamicin injections (100 mg/kg) were given intravenously daily for 10 days to the dogs in Group A, while the Group B dogs served as the untreated control. After the 10 days of injections, blood was collected from the dogs for re-assay of the serum biochemistry. Liver and kidney tissues were processed for histopathology. Results showed that in addition to the significant (p < 0.01) increase in serum levels of creatinine (14-fold), urea (3-fold), and uric acid (4-fold) in the Group A dogs following the gentamicin injections, there were significant (p < 0.01) multiple fold increases in the serum activities of alanine aminotransferase 6-fold), aspartate aminotransferase (5-fold), alkaline phosphatase (3-fold), and serum bilirubin levels (5-fold). In both Group A and B dogs, there were no significant alterations (p > 0.05) in the levels of serum proteins and total cholesterol after the injections. Histological study revealed severe damage to the liver and kidney parenchyma in the Group A dogs only. It was concluded that in addition to kidney damage, the administration of nephrotoxic doses of gentamicin to dogs led to significant hepatocellular and hepatobiliary damage, but had no significant effect on the hepatic synthetic function (serum levels of total cholesterol, total proteins, albumin and globulins). Due consideration should be given to the effects of gentamicin on the liver when higher doses are used experimentally or clinically in dogs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

Download references

Acknowledgements

The authors acknowledge the research support of the Biomedical Research Support Unit of the Foundation for Education and Research in Health, Nsukka in the biochemical analysis of the serum samples and the technical support of staff of the Department of Veterinary Pathology and Microbiology, University of Nigeria, Nsukka, in relation to the care and handling of the dogs used for the study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thelma Ebele Ihedioha.

Ethics declarations

Statement of Animal Rights

The dogs used for the study were humanely handled all through the study. The protocol for care and use of the dogs for the experiment was approved by the Institutional Animal Care and Use Committee of the Faculty of Veterinary Medicine, University of Nigeria Nsukka (Approval Reference Number: FVM-UNN-IACUC-2021-0264). All institutional and national guidelines for the care and use of laboratory animals were followed.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ezema, A.S., Ihedioha, T.E., Num-Adom, S.M. et al. Alterations in serum activity of hepatocellular enzymes, levels of liver function markers, and liver histology of dogs given high (nephrotoxic) doses of gentamicin. Comp Clin Pathol 31, 115–122 (2022). https://doi.org/10.1007/s00580-021-03314-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00580-021-03314-0

Keywords

Navigation